Financial Performance - The company's operating revenue for Q1 2023 reached ¥930,792,120.15, representing a 15.10% increase compared to ¥808,667,287.75 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥147,199,342.42, a 21.47% increase from ¥121,180,965.35 year-on-year[4] - Basic earnings per share for Q1 2023 increased to ¥0.27, up 22.73% from ¥0.22 in the previous year[4] - The company reported a total profit of CNY 212,650,690.55 for Q1 2023, up 41.1% from CNY 150,691,797.70 in the same quarter last year[23] - Total comprehensive income for Q1 2023 reached ¥157,743,872.79, up from ¥111,299,985.87 in Q1 2022, representing an increase of approximately 41.7%[24] - Net profit attributable to the parent company was ¥150,279,161.27, compared to ¥112,139,389.14 in the same period last year, marking a growth of about 33.9%[24] Cash Flow - Cash flow from operating activities for Q1 2023 was ¥271,087,408.44, showing a significant increase of 60.24% compared to ¥169,175,858.16 in the same period last year[4] - Net cash flow from operating activities was ¥271,087,408.44, significantly higher than ¥169,175,858.16 in Q1 2022, indicating a rise of approximately 60.3%[26] - Cash inflow from investment activities totaled ¥2,813,295,828.58, compared to ¥850,083,410.21 in the previous year, showing a substantial increase of about 231.5%[26] - Net cash flow from investment activities was ¥1,361,244,349.59, a turnaround from a negative cash flow of ¥85,897,198.17 in Q1 2022[26] - Cash and cash equivalents at the end of the period reached ¥2,940,102,692.11, up from ¥1,008,902,230.19 at the end of Q1 2022, representing an increase of approximately 191.5%[27] - Total cash inflow from operating activities was ¥859,575,034.62, slightly down from ¥888,620,847.48 in the previous year[25] - Total cash outflow from operating activities decreased to ¥588,487,626.18 from ¥719,444,989.32, reflecting a reduction of about 18.2%[26] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥6,885,167,093.64, a 4.57% increase from ¥6,584,482,315.79 at the end of the previous year[4] - The company's cash and cash equivalents at the end of Q1 2023 were ¥294,795,220, reflecting a 119.17% increase from the beginning of the period[9] - Accounts receivable increased to CNY 252,028,887.45 from CNY 195,449,513.17, reflecting a growth in sales or services rendered[17] - The total current assets rose to CNY 4,886,469,752.37, compared to CNY 4,616,865,732.86 at the beginning of the year, showing a positive trend in asset management[17] - Non-current assets totaled CNY 1,998,697,341.27, up from CNY 1,967,616,582.93, indicating ongoing investments in long-term assets[18] - The company's total liabilities increased, with accounts payable rising to CNY 291,734,065.74 from CNY 208,301,944.41, suggesting higher operational costs or increased purchasing activity[18] - Total liabilities rose to CNY 1,601,535,922.80, compared to CNY 1,456,588,992.67 in the previous year, marking an increase of 9.9%[20] - The total equity attributable to shareholders of the parent company increased to CNY 5,259,515,606.64, up from CNY 5,114,136,775.46, reflecting a growth of 2.8%[20] Research and Development - Research and development expenses for Q1 2023 amounted to ¥15,018,600, representing a 92.57% increase year-on-year, indicating a focus on clinical research[9] - Research and development expenses increased significantly to CNY 15,018,634.57, up 92.5% from CNY 7,798,926.88 in Q1 2022[22] Market Strategy - The company is focusing on expanding its market presence and enhancing its service offerings, although specific new products or technologies were not detailed in the report[16] - The company plans to continue expanding its market presence and investing in new technologies to enhance service offerings[1] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,926, indicating a stable shareholder base[10] - The report indicates that the actual controller, Su Qingcan, holds a total of 352,796,200 shares, representing 63.00% of the company's total shares, reflecting strong insider confidence[14] Audit Information - The company did not undergo an audit for the Q1 2023 report[28]
华厦眼科(301267) - 2023 Q1 - 季度财报